Welcome to our dedicated page for Kairos Pharma, LTD. SEC filings (Ticker: KAPA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kairos Pharma SEC filings document regulatory disclosures for a clinical-stage oncology company, including Form 8-K reports on clinical updates for ENV-105 in metastatic castration-resistant prostate cancer and non-small cell lung cancer. The filings also record material agreements tied to oncology asset rights, including license novations involving Cedars-Sinai patents and TRC105/CD105 technology.
Other filings describe proposed oncology asset transactions, executive and director equity compensation under the 2023 Equity Incentive Plan, cash bonus approvals, furnished press releases, and exhibit materials. These records outline governance actions, capital-stock award mechanics, intellectual-property and license arrangements, and event disclosures relevant to Kairos Pharma's development-stage business.
Kairos Pharma, Ltd. (KAPA) reported an insider equity award on a Form 4. Director Rahul Singhvi received 19,084 restricted stock units (RSUs) of common stock on 10/08/2025 under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. These 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date and were recorded at a price of $0.00, reflecting that this is an equity award, not an open-market purchase.
Following this grant, Singhvi beneficially owns 49,204 RSUs, all of which remain subject to vesting conditions and are reported as directly held. The filing is made by a single reporting person in the capacity of director, and it documents non-derivative equity compensation rather than any sale of shares.
Kairos Pharma (KAPA) reported an equity award to its Chief Financial Officer, Doug Samuelson. On 10/08/2025, he received 152,672 restricted stock units (RSUs) of common stock under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan at a price of $0.00 per share. These RSUs are scheduled to vest in full on the first anniversary of the grant date.
Following this grant, Samuelson beneficially owns 293,039 common shares and RSUs in total, consisting of 140,367 shares of common stock and 152,672 RSUs that remain subject to vesting, all held in direct ownership.
Kairos Pharma (KAPA) reported an insider equity grant to its CEO and Chairman, John S. Yu, who is also a director and 10% owner. On 10/08/2025, he received 190,840 restricted stock units (RSUs) of common stock under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan, with all 190,840 RSUs scheduled to vest on the first anniversary of the grant date. Following this award, he directly beneficially owns 230,105 shares of common stock, which consist of 34,599 shares and 195,506 RSUs that remain subject to vesting, and indirectly holds 5,316,572 shares through The Yu Family Trust, where he is trustee. This filing reflects equity-based compensation and confirms his significant ongoing ownership stake.
Kairos Pharma (KAPA) reported Q3 2025 results. The company recorded a net loss of $1.4 million for the quarter and $4.1 million for the nine months ended September 30, 2025, with no revenue reported. Operating expenses rose as development advanced: R&D was $608k in Q3 ($1.6 million year‑to‑date) and G&A was $827k in Q3 ($2.6 million year‑to‑date).
Liquidity improved through 2025 financings. Cash and cash equivalents were $5.6 million and shareholders’ equity was $7.7 million at September 30, 2025. Year‑to‑date financing cash inflows included $3.1 million net from January pre‑funded units and $3.6 million from the equity line of credit. The company expects current cash to fund operations for at least 12 months from the filing date. Common shares outstanding were 20,821,353 as of November 14, 2025. Subsequent events include a $1.143 million Lonza agreement tied to ENV105 Phase 3 manufacturing preparation and new RSU grants for executives and directors.
Kairos Pharma (KAPA) reported new equity awards and bonuses. On October 8, 2025, the Compensation Committee approved an aggregate $950,000 in restricted stock units (RSUs) under the 2023 Equity Incentive Plan for executive officers and directors, calculated at a per share price of $1.31 (the closing price on the grant date). Awards include: John S. Yu 190,840 RSUs valued at $250,000; Neil Bhomick 171,756 RSUs valued at $225,000; Ramachandran Murali 152,672 RSUs valued at $200,000; Doug Samuelson 152,672 RSUs valued at $200,000. Independent directors Hyun W. Bae, Hansoo Michael Keyoung, and Rahul Singhvi each received 19,084 RSUs valued at $25,000.
Each RSU converts into one share upon vesting on October 8, 2026, subject to continuous service, with full acceleration upon a change in control as defined in the Plan. The Committee also approved executive cash bonuses totaling $227,500 for fiscal 2024: Yu $87,500; Bhomick $50,000; Murali $40,000; Samuelson $50,000. The shares underlying these RSUs are registered on Form S-8.
Kairos Pharma, Ltd. reported that its board approved two novation agreements that move key license rights from its wholly owned subsidiary Enviro Therapeutics, Inc. directly to Kairos. Under a novation with Cedars-Sinai Medical Center, the exclusive licenses for two patent families covering DNA-based disease treatments and tumor sensitization technologies are now held by Kairos, which also assumes all related obligations and liabilities while Enviro is released from them.
A separate novation with Tracon Pharmaceuticals, Inc. transfers Enviro’s rights and obligations under a license and supply agreement for TRC105 and CD105 technologies to Kairos. The company also announced it was selected to present Phase 2 clinical data on apalutamide plus carotuximab in advanced castration-resistant prostate cancer at the European Society for Medical Oncology Congress in Berlin.
Kairos Pharma, Ltd. filed an 8-K to share that it has issued a press release announcing positive efficacy data from its ongoing Phase 2 clinical trial of ENV105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC). The company is also hosting a virtual key opinion leader event on September 18, 2025 at 5 p.m. ET / 2 p.m. PT to discuss and provide perspective on these data.
The press release is furnished as Exhibit 99.1 and the slide presentation for the event is furnished as Exhibit 99.2. This information is being furnished, not filed, under the Exchange Act, which means it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings.
Kairos Pharma, Ltd. reported that it will host a premier key opinion leader (KOL) event on September 18, 2025 at 5 p.m. ET / 2 p.m. PT. The event will focus on diverse perspectives regarding interim efficacy results from a Phase 2 trial of its lead candidate, ENV105, in treating advanced prostate cancer patients. The company furnished a related press release as Exhibit 99.1, noting that this information is being provided under an “Other Events” item and is treated as furnished rather than filed under the securities laws.
Kairos Pharma, Ltd. filed a report describing a recent corporate update. On September 3, 2025, the company issued a press release announcing its participation in the World Lung Cancer Conference in Barcelona, Spain. At this meeting, Principal Investigator Dr. Karen Reckamp is scheduled to present initial Phase 1 data for the company’s drug candidate ENV105 in non-small cell lung cancer.
The conference is taking place from September 6–9, 2025 at the Fira de Barcelona Gran Via. The press release with additional details is provided as Exhibit 99.1 to the report and is being furnished rather than filed, meaning it is not incorporated into the company’s other Securities Act or Exchange Act filings by default.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 884,938 shares of Kairos Pharma, Ltd. common stock, representing 4.99% of the class. Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and exercises shared voting and dispositive power over the securities under an Investment Management Agreement. Neither Armistice Capital nor Mr. Boyd claim sole voting or sole dispositive power; both report 0 sole and 884,938 shared voting and dispositive powers. The filing states the shares are held in the ordinary course of business and not acquired to influence control. The Schedule 13G/A is jointly filed and signed by Steven Boyd as Managing Member.